Momenta And Baxter To Team Up On Biosimilars As U.S. Regulatory Pathway Becomes Clearer
By
Joseph Haas / Email the Author / “The Pink Sheet” DAILY Dec. 27, 2011
Word Count: 1305 / Article # 14111227001
Executive Summary
Momenta believes its biologic characterization approach combined with Baxter’s commercial expertise in biologics will put the companies’ joint effort in developing biosimilars over the top in what is poised to become a very competitive space.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.